Evidence map›Paper›PMID 30818864›Full record

ArticleInternational journal of molecular sciences2019

Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel.

Apriliana Cahya Khayrani, Hafizah Mahmud, Aung Ko Ko Oo, Maram H Zahra, Miharu Oze, Juan Du, Md Jahangir Alam, Said M Afify, Hagar A Abu Quora, Tsukasa Shigehiro and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. A Journey to Reach the Ovary Using Next-Generation Technologies.International journal of molecular sciences · 2023
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 3 countries.

Apriliana Cahya KhayraniDepartment of Medical Bioengineering, Graduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan. phrw1rm8@s.okayama-u.ac.jp.
Hafizah MahmudDepartment of Medical Bioengineering, Graduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan. hfzhmhmd@gmail.com.
Aung Ko Ko OoDepartment of Medical Bioengineering, Graduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan. kokooo.aung@gmail.com.
Maram H ZahraLaboratory of Nano-Biotechnology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama 700-8530, Japan. maram@okayama-u.ac.jp.
Miharu OzeDepartment of Medical Bioengineering, Graduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan. px934zug@s.okayama-u.ac.jp.
Juan DuDepartment of Medical Bioengineering, Graduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan. jahangir-geb@sust.edu.
Md Jahangir AlamDepartment of Medical Bioengineering, Graduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan. jahangir-geb@sust.edu.
Said M AfifyDepartment of Medical Bioengineering, Graduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan. jahangir-geb@sust.edu.
Hagar A Abu QuoraLaboratory of Nano-Biotechnology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama 700-8530, Japan. pfgg90pn@s.okayama-u.ac.jp.
Tsukasa ShigehiroDepartment of Medical Bioengineering, Graduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan. Tsukasa.Shigehiro@roswellpark.org.
Anna Sanchez CalleDivision of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo 104-0045, Japan. annasc.nit@gmail.com.
Nobuhiro OkadaLaboratory of Nano-Biotechnology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama 700-8530, Japan. aseno@okayama-u.ac.jp.
Akimasa SenoLaboratory of Nano-Biotechnology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama 700-8530, Japan. annasc.nit@gmail.com.
Koki FujitaEnsuiko Sugar Refining Co., Ltd., Tokyo 103-0012, Japan. koki_fujita@pearlace.co.jp.
Hiroki HamadaFaculty of Science, Okayama University of Science, Okayama 700-0005, Japan. hamada@dls.ous.ac.jp.
Yuhki SenoGraduate School of Pharmaceutical Science, Tokushima University, Tokushima 770-8505, Japan. s20b028@sci.kusa.ac.jp.
Tadakatsu MandaiFaculty of Life Science, Kurashiki University of Science and the Arts, Kurashiki 712-8505, Japan. ted@chem.kusa.ac.jp.
Masaharu SenoDepartment of Medical Bioengineering, Graduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan. mseno@okayama-u.ac.jp.
Okayama University · JPOkayama University of Science · JPKurashiki University of Science and the Arts · JPEnsuiko Sugar Refining (Japan) · JPNational Cancer Research Institute · GBRoswell Park Comprehensive Cancer Center · US

Funding

Grant-in-Aid for JSPS KAKENHI Early-Career Scientists Grant JP18K15243the Grant-in-Aid for Scientific Research (A) 25242045
6 · The paper itself

Abstract

Paclitaxel (PTX) is one of the front-line drugs approved for the treatment of ovarian cancer. However, the application of PTX is limited due to the significant hydrophobicity and poor pharmacokinetics. We previously reported target-directed liposomes carrying tumor-selective conjugated antibody and encapsulated glycosylated PTX (gPTX-L) which successfully overcome the PTX limitation. The tubulin stabilizing activity of gPTX was equivalent to that of PTX while the cytotoxic activity of gPTX was reduced. In human ovarian cancer cell lines, SK-OV-3 and OVK18, the concentration at which cell growth was inhibited by 50% (IC

Indexed as

Molecular Targeted TherapyAntibodies, MonoclonalCell Line, TumorCell ProliferationFemaleGlycosylationHumansHyaluronan ReceptorsLiposomesOvarian NeoplasmsPaclitaxelAntibodies, MonoclonalCD44 protein, humanHyaluronan ReceptorsLiposomesPaclitaxelCD44glycosylated paclitaxelliposomemodified paclitaxelovarian cancerspecific targeting

Identifiers

PMID30818864
PMCPMC6429518
OpenAlexW2917546369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.